I read with interest the American Gastroenterological Association clinical practice update by Garcia-Tsao et al1 on the use of vasoactive drugs and intravenous albumin in cirrhosis. All the best practice advice statements are quite helpful for clinicians in managing the important complications of portal hypertension. However, the statements suggest that after initial endoscopic hemostasis, vasoactive drugs should be continued for 2–5 days to prevent early re-bleeding. This issue actually requires further clarification.
We will be happy to hear your thoughts